The present invention discloses Fuke Qianjin Capsules and a quality control method therefor. The capsules are made of Radix Et Caulis Flemingiae, Caulis Mahoniae, Herba Andrographis, Zanthoxylum dissitum Hemsl., Caulis Spatholobi, Radix Angelicae Sinensis, Radix Codonopsis, and Radix Rosa Laevigata as raw materials. Each of the Fuke Qianjin Capsules contains not less than 2.0 mg of Z-ligustilide, and a total amount of andrographolide and dehydroandrographolide is not less than 1.9 mg. A new standard for controlling quality of the Fuke Qianjin Capsules has been established through an analysis of chemical ingredients in the Fuke Qianjin Capsules. This standard adds a variety of core ingredient content to the existing pharmacopoeia standards. According to the Fuke Qianjin Capsules made in this range, the consistency of effects between different batches is more stable. Moreover, the more the types of core ingredients are limited, the more stable the consistency of the drug effect.

The present invention discloses Fuke Qianjin Capsules and a quality control method therefor. The capsules are made of Radix Et Caulis Flemingiae, Caulis Mahoniae, Herba Andrographis, Zanthoxylum dissitum Hemsl., Caulis Spatholobi, Radix Angelicae Sinensis, Radix Codonopsis, and Radix Rosa Laevigata as raw materials. Each of the Fuke Qianjin Capsules contains not less than 2.0 mg of Z-ligustilide, and a total amount of andrographolide and dehydroandrographolide is not less than 1.9 mg. A new standard for controlling quality of the Fuke Qianjin Capsules has been established through an analysis of chemical ingredients in the Fuke Qianjin Capsules. This standard adds a variety of core ingredient content to the existing pharmacopoeia standards. According to the Fuke Qianjin Capsules made in this range, the consistency of effects between different batches is more stable. Moreover, the more the types of core ingredients are limited, the more stable the consistency of the drug effect.

The present invention discloses Fuke Qianjin Capsules and a quality control method therefor. The capsules are made of Radix Et Caulis Flemingiae, Caulis Mahoniae, Herba Andrographis, Zanthoxylum dissitum Hemsl., Caulis Spatholobi, Radix Angelicae Sinensis, Radix Codonopsis, and Radix Rosa Laevigata as raw materials. Each of the Fuke Qianjin Capsules contains not less than 2.0 mg of Z-ligustilide, and a total amount of andrographolide and dehydroandrographolide is not less than 1.9 mg. A new standard for controlling quality of the Fuke Qianjin Capsules has been established through an analysis of chemical ingredients in the Fuke Qianjin Capsules. This standard adds a variety of core ingredient content to the existing pharmacopoeia standards. According to the Fuke Qianjin Capsules made in this range, the consistency of effects between different batches is more stable. Moreover, the more the types of core ingredients are limited, the more stable the consistency of the drug effect.

A method to prepare a therapeutic balm is disclosed. A first phase solution is prepared in an oak barrel using a grain neutral spirit. The first phase is mixed for 10 minutes per day for a month to prepare a second phase solution. The second phase solution is filtered at least twice to prepare a filtrate. The filtrate and third phase components are mixed to prepare a third phase solution. The third phase solution is mixed with a distilled wine liquor to prepare a fourth phase solution. The fourth phase solution is mixed at least twice a day for a month to prepare a fifth phase solution. The fifth phase solution is mixed with cranberry juice, pomegranate juice, and raspberry juice to prepare a sixth phase solution. The sixth phase solution is stored in a ceramic bottle for a least six months at room temperature to prepare a therapeutic balm.

A method to prepare a therapeutic balm is disclosed. A first phase solution is prepared in an oak barrel using a grain neutral spirit. The first phase is mixed for 10 minutes per day for a month to prepare a second phase solution. The second phase solution is filtered at least twice to prepare a filtrate. The filtrate and third phase components are mixed to prepare a third phase solution. The third phase solution is mixed with a distilled wine liquor to prepare a fourth phase solution. The fourth phase solution is mixed at least twice a day for a month to prepare a fifth phase solution. The fifth phase solution is mixed with cranberry juice, pomegranate juice, and raspberry juice to prepare a sixth phase solution. The sixth phase solution is stored in a ceramic bottle for a least six months at room temperature to prepare a therapeutic balm.

A method to prepare a therapeutic balm is disclosed. A first phase solution is prepared in an oak barrel using a grain neutral spirit. The first phase is mixed for 10 minutes per day for a month to prepare a second phase solution. The second phase solution is filtered at least twice to prepare a filtrate. The filtrate and third phase components are mixed to prepare a third phase solution. The third phase solution is mixed with a distilled wine liquor to prepare a fourth phase solution. The fourth phase solution is mixed at least twice a day for a month to prepare a fifth phase solution. The fifth phase solution is mixed with cranberry juice, pomegranate juice, and raspberry juice to prepare a sixth phase solution. The sixth phase solution is stored in a ceramic bottle for a least six months at room temperature to prepare a therapeutic balm.

The present invention addresses the problem of providing an ultraviolet light-induced inflammation suppressing agent. The present invention is based on the finding that an alternative autophagy (Atg5/Atg7-independent autophagy) participates in the suppression of ultraviolet light-induced inflammation. Thus, the above problem is solved by providing an alternative autophagy inducing agent.

The present invention addresses the problem of providing an ultraviolet light-induced inflammation suppressing agent. The present invention is based on the finding that an alternative autophagy (Atg5/Atg7-independent autophagy) participates in the suppression of ultraviolet light-induced inflammation. Thus, the above problem is solved by providing an alternative autophagy inducing agent.

The present invention addresses the problem of providing an ultraviolet light-induced inflammation suppressing agent. The present invention is based on the finding that an alternative autophagy (Atg5/Atg7-independent autophagy) participates in the suppression of ultraviolet light-induced inflammation. Thus, the above problem is solved by providing an alternative autophagy inducing agent.

A system and method of applying a slick surface, such as silicone epoxy, is applied on a vertical wall (on or around the perimeter of a structure), as a means of preventing (bark) scorpions (or other insects/arachnids) from climbing up walls. The system is intended, in part, to keep the Arizona bark scorpions out of homes. Vertical surface areas around the home are treated with a material such as silicone. A clear silicone epoxy, that when dry, prevents scorpions from climbing vertically up into a home or structure. This non-toxic epoxy is applied to the base of a home, including door thresholds, steps or other parts of a home which makes contact with the ground. The epoxy is applied to the area by sprayer.